TD2 clients receive expert clinical trial management and access to an array of clinical trial sites. In order to better serve our clients, TD2 created a network of clinical trial sites around the world solely focused on pancreatic cancer. This network, known as the Pancreatic Cancer Research Team (PCRT), is a disease-specific consortium that allows for a global network of clinical trial sites ready to use drugs with pancreatic cancer applications quickly and effectively.

TD2 clients are able to use the PCRT resources to shorten the start up time for pancreatic cancer trials, as well as select state-of-the-art clinical facilities that fit their criteria both in the US and abroad. This specific disease-focused clinical network adds to TD2 being a "one-stop shop" for drug development.

PCRT is a non-profit organization with a sole focus on accelerating treatments and clinical trials for pancreatic cancer patients. Since it's inception in 2003, PCRT has grown to include 33 international institutions with sites in the US and three European countries. Sixty principal investigators represent the 22 highly distinguished pancreatic cancer sites.

The PCRT administration is organized as a site management organization to facilitate the PCRT member institutions in opening those clinical trails that PCRT Investigators consider to have the most promise, or most effective treatment for pancreatic cancer patients. The PCRT member institutions are independently operated, and autonomous from the PCRT administration.

Please visit www.PCRT.org or contact Amy Stoll at astoll@tgen.org or 602-358-8319.